iShares S&P 500 ETF

IVV

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

AVA Risk Group Limited

AVA

Ava Risk Group Ltd. provides risk management services and technologies. The company is headquartered in Mulgrave, Victoria. The company went IPO on 2015-05-11. The firm is engaged in the provision of security technology products for perimeter intrusion detection solutions. The firm operate through three segments: Detect, Access, and Illuminate. Detect segment manufactures and markets smart fiber optic sensing systems for security and condition monitoring for a range of applications including perimeters, pipelines, conveyors, power cables and data networks. Access segment specializes in the development, manufacture and supply of high security biometric readers, security access control and electronic locking products. Illuminate segment specializes in the development and manufacture of illuminators, automatic number plate recognition (ANPR) cameras and perimeter detectors. Its subsidiaries include FFT MENA Pty Ltd, Future Fibre Technologies (US) Inc., and MaxSec Group Pty Ltd.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).

Change Financial Limited

CCA

Change Financial Ltd. engages in the provision of mobile digital banking. The company is headquartered in Brisbane, Queensland. The company went IPO on 2016-06-30. The firm leverages scalable technology to provide payment solutions, card issuing and testing to banks and fintechs. Its principal activity includes commercialization and ongoing development of its payments management platform and payment testing solution. Its core products include Vertexon Payments as a Service (PaaS) and PaySim. Vertexon (PaaS) integrates with the core systems of banks and fintechs, enabling the delivery of physical, digital, and virtual card solutions to their customers. The company includes integrated features such as Apple Pay, Google Pay, Samsung Pay and Buy Now Pay Later (BNPL) services. PaySim is a payment testing solution, which enables banks and fintechs to complete end-to-end testing of their payment platforms and processes from a desktop. The company also provides the default standard for payments testing for many Australian companies, including Australia’s domestic card payment service EFTPO.

SPDR S&P/ASX 200 ETF

STW

STW.AX was created on 2001-08-24 by SPDR. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6060.86m in AUM and 201 holdings. The Investment Objective of SPDR S&P/ASX 200 ETF is to match the performance of its Index before fees and other costs.